Michael A Mendall

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/334941/publications.pdf

Version: 2024-02-01

24 papers 1,221 citations

567281 15 h-index 642732 23 g-index

25 all docs

25 docs citations

25 times ranked

1975 citing authors

#	Article	IF	Citations
1	Obesity and Risk of Crohn's Disease Half the Story. Clinical Gastroenterology and Hepatology, 2023, 21, 1121-1122.	4.4	1
2	Childhood growth and risk of inflammatory bowel disease: a population-based study of 317,030 children. Scandinavian Journal of Gastroenterology, 2019, 54, 863-868.	1.5	4
3	Body mass index in young men and risk of inflammatory bowel disease through adult life: A population-based Danish cohort study. Scientific Reports, 2019, 9, 6360.	3.3	16
4	Childhood body mass index and risk of inflammatory bowel disease in adulthood: a population-based cohort study. American Journal of Gastroenterology, 2018, 113, 694-701.	0.4	32
5	Relation of body mass index to risk of developing inflammatory bowel disease amongst women in the Danish National Birth Cohort. PLoS ONE, 2018, 13, e0190600.	2.5	23
6	Faecal calprotectin: factors affecting levels and its potential role as a surrogate marker for risk of development of Crohn's Disease. BMC Gastroenterology, 2016, 16, 126.	2.0	22
7	European Crohnâ \in ^M s and Colitis Organisation Topical Review on IBD in the Elderly: Table 1 Journal of Crohn's and Colitis, 2016, 11, jjw188.	1.3	79
8	Treatment of Crohn's Disease with an IgG4-Guided Exclusion Diet: A Randomized Controlled Trial. Digestive Diseases and Sciences, 2016, 61, 1148-1157.	2.3	51
9	Diverticular Disease and Vascular Diseases: A Shared Responsiveness to Injury Is Likely to Be the Underlying Mechanism. Clinical Gastroenterology and Hepatology, 2015, 13, 1375.	4.4	O
10	Determinants of Weight Loss prior to Diagnosis in Inflammatory Bowel Disease: A Retrospective Observational Study. Gastroenterology Research and Practice, 2014, 2014, 1-7.	1.5	29
11	Environment and Risk of Crohn $\hat{E}^{1}\!\!/\!\!4$ s Disease. Inflammatory Bowel Diseases, 2014, 20, E11-E12.	1.9	1
12	Abdominal adiposity is the main determinant of the C-reactive response to injury in subjects undergoing inguinal hernia repair. Journal of Inflammation, 2013, 10, 5.	3.4	5
13	Advanced age influences the dynamic changes in circulating C-reactive protein following injury. Journal of Clinical Pathology, 2013, 66, 695-699.	2.0	12
14	Incidence and survival of oesophageal and gastric cancer in England between 1998 and 2007, a population-based study. BMC Cancer, 2012, 12, 11.	2.6	58
15	Is Obesity a Risk Factor for Crohn's Disease?. Digestive Diseases and Sciences, 2011, 56, 837-844.	2.3	95
16	Bowel Inflammation as Measured by Fecal Calprotectin. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 279-284.	2.5	189
17	Emerging role of calprotectin in gastroenterology. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 756-762.	2.8	91
18	Increased Risk of Atherosclerosis Is Confined to CagA-PositiveHelicobacter pyloriStrains. Stroke, 2003, 34, 610-615.	2.0	105

#	Article	IF	CITATIONS
19	Proton pump inhibitors are associated with elevation of faecal calprotectin and may affect specificity. European Journal of Gastroenterology and Hepatology, 2003, 15, 573-574.	1.6	73
20	Effect of the CD14 promoter polymorphism on liver function tests and its association with alcohol and obesity. European Journal of Gastroenterology and Hepatology, 2003, 15, 1317-1322.	1.6	8
21	Effect of Treatment for <i>Chlamydia pneumoniae</i> and <i>Helicobacter pylori</i> on Markers of Inflammation and Cardiac Events in Patients With Acute Coronary Syndromes. Circulation, 2002, 106, 1219-1223.	1.6	178
22	A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders. European Journal of Gastroenterology and Hepatology, 2002, 14, 409-412.	1.6	108
23	Lymphocytic Gastritis and Helicobacter pylori: Reluctant Mucosal Partners?. Helicobacter, 2000, 5, 248-249.	3.5	2
24	<i>Chlamydia pneumoniae</i> Serology, Lung Function Decline, and Treatment for Respiratory Disease. American Journal of Respiratory and Critical Care Medicine, 2000, 161, 493-497.	5.6	25